Literature DB >> 15222671

Alendronate-induced auditory hallucinations and visual disturbances.

Craig I Coleman1, Kristen A Perkerson, Anne Lewis.   

Abstract

A 79-year-old Caucasian woman who had been taking alendronate 10 mg/day for over 2 years to prevent osteoporosis reported hearing "voices in her head" along with red-colored visual disturbances. These auditory hallucinations and visual disturbances began shortly after her regimen was changed from alendronate 10 mg/day to 70 mg once/week. Assessment of causality using the Naranjo and Jones algorithms revealed a "probable" and "highly probable" relationship, respectively, between this adverse drug event and the switch from daily to weekly alendronate therapy. Other bisphosphonates, such as etidronate and pamidronate, have caused both reversible and irreversible auditory, visual, and olfactory hallucinations beginning 2 hours--1 week after drug administration. The mechanism behind these adverse effects is unknown but is thought to be independent of calcium homeostasis. Clinicians should be aware of central nervous system toxicity as a rare but potential adverse effect associated with bisphosphonates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222671     DOI: 10.1592/phco.24.8.799.36062

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  Alendronate treatment induces IL-1B expression and apoptosis in glioblastoma cell line.

Authors:  Paola Maura Tricarico; Angeladine Epate; Fulvio Celsi; Sergio Crovella
Journal:  Inflammopharmacology       Date:  2017-06-23       Impact factor: 4.473

2.  Hepatotoxicity induced by alendronate therapy.

Authors:  B Yanik; C Turkay; H Atalar
Journal:  Osteoporos Int       Date:  2007-01-17       Impact factor: 5.071

3.  Intravenous bisphosphonates for postmenopausal osteoporosis.

Authors:  Peyman Mottaghi
Journal:  J Res Med Sci       Date:  2010-05       Impact factor: 1.852

4.  Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.

Authors:  Anselm Mak; Mike W L Cheung; Roger Chun-Man Ho; Alicia Ai-Cia Cheak; Chak Sing Lau
Journal:  BMC Musculoskelet Disord       Date:  2009-09-21       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.